Document:

Memorandum of Understanding

 Exhibit 10.39 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 MEMORANDUM OF UNDERSTANDING 

ENTERED INTO AS OF MARCH 7, 2011. 
  

			
	 AMONG:
	  	BIOAMBER INC., a legal entity duly existing, having its head office located at 1250 Rene-Levesque West, Suite 4110, Montreal, Quebec, Canada, H3B 4W8, represented for the
purposes hereof by Mr. Jean-François Huc, its President, duly authorized as he so declares;
		
		  	(“BioAmber”)
		
	 AND:
	  	MITSUI & CO., LTD., a legal entity duly existing, having its principal place of business located at [***], represented for the purposes hereof by [***], duly
authorized as he so declares;
		
		  	(“Mitsui”)
		
	 AND:
	  	MITSUBISHI CHEMICAL CORPORATION, a legal entity duly existing, having its principal place of business located at [***], represented for the purposes hereof by [***], duly
authorized as he so declares;
		
		  	(“MCC”)
		
		  	(BioAmber, Mitsui and MCC being collectively referred to as the “Parties” and individually as the “Party”)

 WHEREAS BioAmber is dedicated to building a leadership position in the field of green chemistry through the
development and commercialization of succinic acid fermentation and purification technologies, including future innovations to the succinic acid fermentation and purification technologies (the “BioAmber Technology”) that produce
bio-based succinic acid (“Biobased Succinic Acid”); 
 WHEREAS Mitsui, a leader in commodity trading, is committed to
broadening the scope of its green chemical business activities and has identified BioAmber as a strategic partner to do so; 
 WHEREAS
BioAmber and Mitsui have entered into a separate memorandum of understanding on March 7, 2011 to express their intent to build a strategic relationship in the field of Biobased Succinic Acid consisting mainly in the establishment of two
joint-ventures, one to build a Biobased Succinic Acid production plant in North America (the “NA BSA JV”) and a second to build a Biobased Succinic Acid production plant in Asia, preferably in Thailand (the “Asia BSA
JV”); 

  
 - 1 -

 * Confidential treatment requested 

 WHEREAS MCC, who has been engaged in the development of a wide range of products in the fields of
performance materials, health care and chemicals based on proprietary chemistry-based technology platforms, is looking to broaden the scope of its biobased chemical business activities and has identified the BioAmber Technology and Biobased Succinic
Acid as a potential platform to do so; 
 WHEREAS MCC is planning to establish a joint venture with PTT Public Company Limited, a Thai
state-owned SET-listed oil and gas company (“PTT”), in the field of PBS products (the “MCC-PTT JV”); 

WHEREAS BioAmber is currently producing Biobased Succinic Acid from a demonstration plant in France; 

WHEREAS BioAmber, Mitsui and MCC have been considering establishing a strategic relationship in the field of Biobased Succinic Acid consisting of
(i) the joint development and improvement of technologies, based on BioAmber Technology and MCC Technology (hereinafter defined) (ii) the exclusive supply by BioAmber to MCC of Biobased Succinic Acid for the production of biobased PBS, and
(iii) MCC’s participation in the Asia BSA JV (directly or through the eventual MCC-PTT JV); 
 WHEREAS the Parties are now at a
stage where each is prepared to commit significant time and effort to the planning, structuring and financing of these projects and wish to define the scope of their respective undertakings in connection therewith; 

ACCORDINGLY, THE PARTIES AGREE AS FOLLOWS: 
  

	1	STATEMENT OF INTENT  

  

	 	1.1	The intention of the Parties in executing this Agreement is to establish a strategic relationship in the field of Biobased Succinic Acid consisting of (i) the
joint development and improvement of succinic acid production technologies, based on pre-existing technologies owned by BioAmber and MCC in connection with Biobased Succinic Acid, (ii) the exclusive supply by BioAmber to MCC and/or MCC-PTT JV
of Biobased Succinic Acid, and (iii) the establishment of the Asia BSA JV and the building of a Biobased Succinic Acid production plant in Asia, preferably in Thailand. 

 

	 	1.2	To this end, the Parties will invest the necessary time and effort (i) [***], (ii) [***], and (iii) [***]. 

 

	 	1.3	The Parties recognize that adverse events in the fossil fuel, chemical or commodity markets could affect the timing or long term viability of the Biobased Succinic Acid
production plant in Asia, as could competitive forces or unforeseen technical hurdles. The Parties will undertake the respective roles listed below to the commercially best of their abilities and reasonably seek to accomplish the scope and timing
described below. 

  
 - 2 -

 * Confidential treatment requested 

	2	JOINT EVALUATION AND DEVELOPMENT OF TECHNOLOGIES 

  

	 	2.1	In order to allow MCC to evaluate BioAmber Technology and to allow BioAmber to evaluate MCC’s technologies related to the production of Biobased Succinic Acid
(“MCC Technology”): 

  

	 	2.1.1	BioAmber will disclose the BioAmber Technology to MCC 

  

	 	2.1.2	MCC will disclose the MCC Technology to BioAmber, including MCC’s organism having potential application for the production of Biobased Succinic Acid;

  

	 	2.2	The purpose of these evaluations set forth in Section 2.1 above will be to assess the applicability of BioAmber Technology and MCC Technology to improving the
Biobased Succinic Acid production process in order to (i) [***], (ii) [***], and (iii) [***]. Such evaluations will include [***]. 

  

	 	2.3	Concurrently with the disclosure of their respective technologies to each other, MCC and BioAmber will negotiate and execute a joint development and cross-licensing
agreement pursuant to which the terms and conditions governing the collaboration between BioAmber and MCC on the development and use of their respective technologies will be set out, including with respect to the ownership of new technologies
developed and of improvements to existing technologies. 

  

	 	2.4	The timeline for completing the joint development will be as follows: [***] following the effective date of this Agreement, subject to the necessary regulatory
approvals having been obtained. 

  

	3	SUPPLY AGREEMENTS 

  

	 	3.1	Commencing March 2011, BioAmber and Mitsui will be the exclusive supplier to MCC for its Biobased Succinic Acid needs, initially at a price of [***], with the objective
of reducing this price progressively as (i) [***]; and (ii) [***] MCC shall be free to source from third parties any portion of its needs that cannot be supplied by BioAmber and Mitsui. BioAmber and Mitsui will not be liable for any
portion of MCC’s biobased succinic acid needs that BioAmber and Mitsui cannot supply. 

  
 - 3 -

 * Confidential treatment requested 

	 	3.2	 In anticipation of the NA BSA JV’s production plant coming on line, projected to be in 2013, BioAmber and Mitsui will make their best effort to
conclude with MCC by July 1st, 2011 an exclusive, 5
year off-take agreement in which BioAmber and Mitsui will supply all of MCC’s Biobased Succinic Acid needs. This agreement will offer MCC preferential pricing on Biobased Succinic Acid. The Parties will have the option to terminate or make
non-exclusive this off-take agreement when the Asia BSA JV commissions the Asia Plant. In any event, [***] MCC shall be free to source from third parties any portion of its needs that cannot be supplied by BioAmber and Mitsui.

  

	 	3.3	The Asia BSA JV will supply MCC and/or MCC-PTT JV with Biobased Succinic Acid at [***] as set out in an off-take agreement to be negotiated by the Parties.

  

	 	3.4	 By
July 1st 2011, BioAmber and MCC will negotiate a
supply agreement pursuant to which BioAmber will be entitled to purchase a portion of PBS produced by MCC or MCC-PTT JV for subsequent modification and sale by BioAmber’s Sinoven division as modified PBS. The parties shall negotiate in good
faith the annual volumes over the next three years, based on MCC’s production capacity and ability to supply. 

  

	 	3.5	BioAmber will endeavour to provide MCC with PBS commercial opportunities in the fields of automotive parts, food service and consumer goods. 

 

	4	PARTICIPATION IN THE ASIA BSA JV 

  

	 	4.1	The Parties agree that it is their intent, subject to the successful outcome of a feasibility study, to proceed jointly with a Biobased Succinic Acid production plant
having an approximate initial capacity of [***], to be built in Asia, preferably in Thailand (the “Asian Plant”) and to be financed and built through the Asia BSA JV. 

 

	 	4.2	MCC, directly or through MCC-PTT JV, will take an equity participation in the Asia BSA JV [***], subject to Mitsui and BioAmber collectively retaining a controlling
interest in the Asia BSA JV. The MCC or MCC-PTT JV equity stake in the Asia BSA JV will not [***]. 

  

	 	4.3	The Parties will negotiate an operating agreement [***]. 

  

	 	4.4	BioAmber will license the BioAmber Technology to the Asia BSA JV, including all technology innovations in consideration of which BioAmber will receive [***]. In the
event that the BioAmber Technology licensed to the Asia BSA JV incorporates elements of the MCC Technology, BioAmber will pay to MCC [***]. The [***] paid to MCC will be defined in the joint development and cross-licensing agreement described in
section 2.3. 

  

	 	4.5	In the event BioAmber develops a commercially viable technology for converting Biobased Succinic Acid to 1,4 butanediol, MCC and/or MCC-PTT JV will have the option to
initiate a negotiation with BioAmber pursuant to which BioAmber will license such technology to the Asia BSA JV at terms to be negotiated. 

  
 - 4 -

 * Confidential treatment requested 

	 	4.6	The timeline for the Asian plant will be targeted as follows: 

  

	 	4.6.1    	2012: Execute an agreement detailing the structure and operation of the Asia BSA JV and Asian Plant, respective roles, financing, off-take terms, etc.; and

  

	 	4.6.2    	2014/15: Commission the Asian Plant. 

  

	5	RESPONSIBILITIES 

  

	 	5.1	In furtherance of its commitments in the preceding articles, BioAmber agrees to: 

 

	 	5.1.1	Undertake joint development with MCC that seeks to [***] 

  

	 	5.1.2	Seek to [***] 

  

	 	5.1.3	Discuss and negotiate on [***] 

  

	 	5.2	In furtherance of its commitments in the preceding articles, Mitsui agrees to: 

 

	 	5.2.1	Oversee the logistics for supplying MCC with Biobased Succinic Acid from BioAmber’s French demonstration plant and subsequently the NA BSA JV

  

	 	5.2.2	Discuss and negotiate on providing [***] 

  

	 	5.2.3	Coordinate with MCC the site selection process, feedstock sourcing and non-dilutive financing for the Asian Plant 

 

	 	5.2.4	Secure customers and oversee global distribution logistics for the portion of Asian Plant capacity not purchased by MCC and/or MCC-PTT JV; 

 

	 	5.3	In furtherance of its commitments in the preceding articles, MCC agrees to: 

 

	 	5.3.1	Undertake joint development with BioAmber that [***] 

  

	 	5.3.2	Coordinate with Mitsui the site selection process, feedstock sourcing and non-dilutive financing for the Asian Plant 

 

	 	5.3.3	[***], and ensure that all intellectual property related to the BioAmber Technology and MCC Technology is adequately protected 

  
 - 5 -

 * Confidential treatment requested 

	 	5.4	In furtherance of their commitments in the preceding articles, the Parties agree to jointly: 

 

	 	5.4.1	Execute in a timely fashion a joint development and cross-licensing agreement as set out in Section 2.3 of this Agreement 

 

	 	5.4.2	Regularly meet and communicate to exchange information concerning the progress of their respective commitments provided herein; 

 

	 	5.4.3	Complete a feasibility study for the Asian Plant 

  

	 	5.4.4	Negotiate the business model and operation for the Asian Plant; 

  

	 	5.4.5	Negotiate the terms of their collaboration in the Asia BSA JV; and 

  

	 	5.4.6	Negotiate the establishment of the Asia JV, preparation of operating agreements and structure of the financing. 

 

	 	5.5	The Parties designate the following individuals as their respective core team for the purposes of implementing this Agreement: 

 

	 	5.5.1	For BioAmber: 

  

			
	 Name
	  	 Title

	 Jean-François Huc
	  	President
	 Jim Millis
	  	Chief Technology Officer
	 Babette Pettersen
	  	VP Sales & Marketing

  

	 	5.5.2	For Mitsui: 

  

			
	 Name
	  	 Title

	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

  

	 	5.5.3	For MCC: 

  

			
	 Name
	  	 Title

	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

  
 - 6 -

 * Confidential treatment requested 

	6	NEGOTIATION AND EXECUTION OF AGREEMENTS 

  

	 	6.1	Upon execution of this Agreement, the Parties will negotiate in good faith with the view to executing contracts setting out the agreements contained herein in detail as
soon as possible. 

  

	 	6.2	Until such time as the contracts referred to in Section 6.1 are executed and delivered, in form and substance satisfactory to each Party thereto, with approvals of
the board of directors or any other appropriate management body of the said Party, and all governmental approvals required are obtained, no Party shall have any obligation to the establishment of Asia BSA JV or the building of the Asian Plant.

  

	7	TERM AND TERMINATION 

  

	 	7.1	This Agreement shall be effective from the date hereof until [***]. 

  

	 	7.2	This Agreement may be thereafter renewed for successive periods to be agreed upon between the Parties at the end of the initial term, subject to agreement between the
Parties regarding the applicable terms and conditions, to the mutual satisfaction of the Parties. 

  

	 	7.3	Notwithstanding the preceding, in the event of a material deadlock between the Parties concerning any issue arising from this Agreement, any Party may terminate this
Agreement upon written notice to the other to such effect. 

  

	8	PUBLIC DISCLOSURE 

  

	 	8.1	The Parties agree that it is their intent to publicly disclose their proposed relationship described in this Agreement, subject to the parties agreeing on the content
of any press release and the moment of its release. Such public disclosure will aim to raise the visibility of the BioAmber Technology, Mitsui’s participation as a manufacturer and distributor of Biobased Succinic Acid, and MCC’s
participation as a manufacturer and technology provider of Biobased Succinic Acid to secure low cost feedstock for its PBS business. 

  

	9	ASSIGNMENT 

  

	 	9.1	No party may assign its rights and obligations pursuant to this Agreement to any third party without the prior written consent of the other party, which may not be
unreasonably withheld or delayed. 

  
 - 7 -

 * Confidential treatment requested 

	10	NOTICE 

  

	 	10.1	All notice, consents, requests and other communications hereunder shall be in writing in the English language and shall be deemed validly given (i) upon personal
delivery in case of personal delivery or (ii) five (5) days after transmission in case of facsimile (if sent by facsimile, the said notice, consents, requests and communications shall be confirmed by registered mail or major international
delivery services on the following business day) or after being sent in case of registered prepaid airmail letter or major international delivery services, to be served at the following addresses: 

 

					
	 If to BioAmber:
	  	Address:	  	1250 Rene Levesque Blvd West, Suite 4110
		  		  	Montreal, Quebec, Canada H3B-4W8
			
		  	[***]	  	
			
		  	Attention:	  	President, BioAmber Inc.
			
	 With a copy to:
	  	Address:	  	Boivin Desbiens Senécal, g.p.
			
		  		  	[***]
			
	 If to Mitsui:
	  	[***]	  	
			
	 If to MCC:
	  	[***]	  	

  

	11	CONFIDENTIALITY 

  

	 	11.1	This Agreement is subject to the Non-Disclosure Agreement dated November 12, 2010 entered into between BioAmber, Mitsui and MCC (the “NDA”) and
the contents hereof are deemed to be “Confidential Information” as defined in NDA. 

  

	12	GENERAL PROVISIONS 

  

	 	12.1	This Agreement may be modified in whole or in part by common agreement between the parties and solely in writing. 

 

	 	12.2	The titles are used for convenience only and do not affect the significance or the reach of the sections they refer to. 

 

	 	12.3	This Agreement shall be governed by the laws of the State of New York, without regard to its conflicts of law principles, and the Parties agree to attorn to the
exclusive jurisdiction of the courts of the State of New York. 

  

	 	12.4	Unless otherwise specifically agreed by the Parties, each Party shall bear and pay all cost and expense incurred by it to execute this Agreement

  
 - 8 -

 * Confidential treatment requested 

 IN WITNESS WHEREOF, THE PARTIES HAVE EXECUTED THIS AGREEMENT ON THE DATE FIRST ABOVE MENTIONED.

  

			
	BIOAMBER INC.
		
	By:	 	/s/ JEAN-FRANCOIS HUC
		 	JEAN-FRANCOIS HUC
	
	MITSUI & CO., LTD.
		
	By:	 	/ s / [***]
		 	[***]
	
	MITSUBISHI CHEMICAL CORPORATION
		
	By:	 	/ s / [***]
		 	[***]

  
 - 9 -

 * Confidential treatment requestedAncillary Agreement to a Memorandum

 Exhibit 10.40 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 ANCILLARY AGREEMENT TO A MEMORANDUM OF UNDERSTANDING

 ENTERED INTO AS OF JULY 14TH, 2011. 
  

			
	AMONG:	  	BIOAMBER INC., a legal entity duly existing, having its head office located at 1250 Rene-Levesque West, Suite 4110, Montreal, Quebec, Canada, H3B 4W8, represented for the
purposes hereof by Mr. Jean-François Huc, its President, duly authorized as he so declares;
		
		  	(“BioAmber”)
		
	AND:	  	MITSUBISHI CHEMICAL CORPORATION, a legal entity duly existing, having its principal place of business located at [***], represented for the purposes hereof by [***], duly
authorized as he so declares;
		
		  	(“MCC”)
		
	AND:	  	PTT MCC BIOCHEM LTD., a legal entity duly existing, having its principal place of business located at [***], represented for the purposes hereof by [***], duly authorized
as he so declares;
		
		  	(“PTT-MCC”)
		
		  	(BioAmber, MCC and PTT-MCC being collectively referred to as the “Parties” and individually as a “Party”)

 WHEREAS BioAmber, MCC and Mitsui & Co., Ltd. (“Mitsui”) have signed, as of March 7, 2011,
a Memorandum of Understanding setting forth the basis of a strategic relationship in the field of biobased succinic acid, PBS and modified PBS (the “MOU”); 
 WHEREAS, subsequent to the entry into force of the MOU, MCC has established, with PTT Public Limited Company, a joint-venture in the field of PBS products named PTT-MCC BIOCHEM, Ltd.; 

WHEREAS PTT-MCC wishes to confirm to BioAmber that it will be bound by certain provisions of the MOU agreed to by MCC in connection with the
supply to BioAmber of PBS products; 

  
 - 1 -

 * Confidential treatment requested 

 ACCORDINGLY, THE PARTIES AGREE AS FOLLOWS: 

 

	1	SUPPLY OF PBS PRODUCTS 

  

	 	1.1	PTT-MCC hereby agrees that it will supply BioAmber with PBS products in order for BioAmber and its affiliates to manufacture modified PBS products, according to the
terms initially set forth between BioAmber and MCC in the MOU. 

  

	 	1.2	Accordingly, by August 15, 2011, BioAmber and PTT-MCC will negotiate a supply agreement pursuant to which BioAmber will be entitled to purchase a portion of PBS
products produced by PTT-MCC for subsequent modification and sale by BioAmber’s Sinoven division as modified PBS. 

  

	 	 	Nothing provided herein shall be deemed to amend, modify or reduce BioAmber’s or MCC’s rights and obligations under the MOU. 

 

	2	PARTICIPATION IN THE ASIA BSA JV 

  

	 	2.1	PTT-MCC and BioAmber agree that it is their intent, subject to the satisfactory outcome of a feasibility study by both parties, to proceed with a biobased Succinic Acid
production plant, to be built in Thailand (the “Asian Plant”) and to be financed and built through the Asia BSA JV (as defined in the MOU). 

  

	 	2.2	Subject to section 2.1, PTT-MCC will consider taking an equity participation in the Asia BSA JV [***], subject to Mitsui and BioAmber collectively retaining a
controlling interest in the Asia BSA JV. The PTT-MCC equity stake in the Asia BSA JV will not [***] 

  

	 	2.3	Subject to sections 2.1 and 2.2, PTT-MCC and BioAmber will negotiate an operating agreement [***] 

 

	 	2.4	BioAmber will license the BioAmber Technology to the Asia BSA JV, including all technology innovations in consideration of which BioAmber will receive [***]. In the
event that the BioAmber Technology licensed to the Asia BSA JV incorporates elements of the MCC Technology, BioAmber will pay to MCC [***]. The [***] paid to MCC will be defined in the joint development and cross-licensing agreement described in
section 2.3 in the MOU. 

  
 - 2 -

 * Confidential treatment requested 

	 	2.5	In the event BioAmber develops a commercially viable technology for converting Biobased Succinic Acid to 1,4 butanediol, PTT-MCC and BioAmber will have the option to
initiate a negotiation pursuant to which BioAmber may license such technology to the Asia BSA JV at terms to be negotiated and agreed upon by the parties. 

  

	 	2.6	The tentative timeline for the Asian plant will be targeted as follows: 

  

	 	2.6.1 	2012: Execute an agreement detailing the structure and operation of the Asia BSA JV and Asian Plant, respective roles, financing, off-take terms, etc.; and

  

	 	2.6.2 	2014: Commission the Asian Plant 

  

	3	NEGOTIATION AND EXECUTION OF AGREEMENTS 

  

	 	3.1	Upon execution of this Agreement, the Parties will negotiate in good faith with the view to executing contracts setting out the agreements contained herein in detail as
soon as possible. 

  

	4	TERM AND TERMINATION 

  

	 	4.1	This Agreement shall be effective from the date hereof. 

  

	 	4.2	In the event of a material deadlock between the Parties concerning any issue arising from this Agreement, any Party may terminate this Agreement upon written notice to
the other to such effect. 

  

	5	ASSIGNMENT 

  

	 	5.1	No party may assign its rights and obligations pursuant to this Agreement to any third party without the prior written consent of the other party, which may not be
unreasonably withheld or delayed. Notwithstanding the preceding, a Party may assign its rights to any affiliate in which it owns at a minimum a 50% equity stake or an affiliate which owns at a minimum a 50% equity stake in the Party.

  

	6	NOTICE 

  

	 	6.1	All notice, consents, requests and other communications hereunder shall be in writing in the English language and shall be deemed validly given (i) upon personal
delivery in case of personal delivery or (ii) five (5) days after transmission in case of facsimile (if sent by facsimile, the said notice, consents, requests and communications shall be confirmed by registered mail or major international
delivery services on the following business day) or after being sent in case of registered prepaid airmail letter or major international delivery services, to be served at the following addresses: 

  
 - 3 -

 * Confidential treatment requested 

	 	 	If to BioAmber: at the address indicated in the MOU 

  

	 	 	If to MCC:         at the address indicated in the MOU 

 

	 	 	If to PTT-MCC: [***] 

  

	7	CONFIDENTIALITY 

  

	 	This Agreement, its content and any disclosure of information in connection therewith are subject to the Confidentiality Agreement dated June 21, 2011 entered into
between BioAmber S.A.S. and PTTMCC and Mitsui & Co. 

  

	8	GENERAL PROVISIONS 

  

	 	8.1	This Agreement may be modified in whole or in part by common agreement between the parties and solely in writing. 

 

	 	8.2	The titles are used for convenience only and do not affect the significance or the reach of the sections they refer to. 

 

	 	8.3	This Agreement shall be governed by the laws of the State of New York, without regard to its conflicts of law principles, and the Parties agree to attorn to the
exclusive jurisdiction of the courts of the State of New York. 

  

	 	8.4	Unless otherwise specifically agreed by the Parties, each Party shall bear and pay all cost and expense incurred by it to execute this Agreement.

  
 - 4 -

 * Confidential treatment requested 

 IN WITNESS WHEREOF, THE PARTIES HAVE EXECUTED THIS AGREEMENT ON THE DATE FIRST ABOVE MENTIONED.

  

			
		 	BIOAMBER INC.
		
	By:	 	/s/ Jim Millis
		 	Jim Millis

  

			
		 	MITSUBISHI CHEMICAL CORPORATION
		
	By:	 	/s/ [***]
		 	[***]

  

			
		 	PTT MCC BIOCHEM CO., LTD.
		
	By:	 	/s/ [***]
		 	[***]

  
 - 5 -

 * Confidential treatment requested 

 AMENDMENT TO ANCILLARY AGREEMENT 

ENTERED INTO AS OF SEPTEMBER 13TH, 2011. 
  

			
	AMONG:	  	BIOAMBER INC., a legal entity duly existing, having its head office located at 3850 Annapolis Lane North, Minneapolis MN, 55447, represented for the purposes hereof by Mr.
Jean-François Huc, its President & Chief Executive Officer, duly authorized as he so declares;
		
		  	(“BioAmber”)
		
	AND:	  	MITSUBISHI CHEMICAL CORPORATION, a legal entity duly existing, having its principal place of business located at [***], represented for the purposes hereof by [***], duly
authorized as he so declares;
		
		  	(“MCC”)
		
	AND:	  	PTTMCC BIOCHEM LTD., a legal entity duly existing, having its principal place of business located at [***], represented for the purposes hereof by [***], duly authorized
as he so declares;
		
		  	(“PTTMCC”)
		
		  	(BioAmber, MCC and PTT-MCC being collectively referred to as the “Parties” and individually as the “Party”)

 WHEREAS BioAmber, MCC and Mitsui & Co., Ltd. (“Mitsui”) executed a
Memorandum Of Understanding as of March 7, 2011, setting forth the basis of a strategic relationship in the field of bio-based succinic acid (“BSA”), PBS and modified PBS (the “1st
MOU”); 
 WHEREAS the Parties executed an
Ancillary Agreement to a Memorandum Of Understanding as of July 14, 2011 (the “2nd MOU”), which included provisions relating to their participation in the Asia BSA JV (as defined in the 1st MOU) for the purpose of building and operating the Asian Plant (as
defined in the 2nd MOU); 

WHEREAS the Parties are now at a stage where each is prepared to commit significant time and effort to the planning,
structuring and financing of Asia BSA JV and the Asian Plant and wish to define the scope of their respective undertakings in connection therewith by way of an Addendum to the 2nd MOU; 

  
 - 1 -

 * Confidential treatment requested 

 ACCORDINGLY, THE PARTIES AGREE AS FOLLOWS: 

 

	1	STATEMENT OF INTENT 

  

	 	1.1	 The intention of the Parties in executing this Amendment to the 2nd MOU (the “Agreement”) is to work together (i) to complete a feasibility study of the Asia BSA JV
and the Asian Plant, (ii) to prepare the necessary agreements, engineering and permits needed to build the Asian Plant, (iii) to implement the Asia BSA JV, and (iv) to build and commission the Asian Plant.

  

	 	1.2	The Parties have accordingly established a work plan to be executed in 4 phases (the “Work Plan”) and agree to collaborate and use their best efforts
to execute the Work Plan and complete the deliverables provided for therein by the target dates indicated. 

  

	2	WORK PLAN 

  

	 	2.1	Phase 1. Phase 1 of the Work Plan has a target completion date of [***]. 

 

	 	2.1.1	Key Deliverables. Phase 1 of the Work Plan is comprised of the following deliverables: 

 

	 	2.1.1.1	 A feasibility study of the Asian Plant, including the following elements: 

 

	 	 	 [***] 

  

	 	2.1.1.2	  Negotiation in good faith of terms and conditions of the Asia BSA JV and the Asian Plant on the basis of terms set out in the 1st MOU and the
2nd MOU and drafting the Transaction Documents (as defined
in Section 12.1). 

  

	 	2.1.1.3	 Securing a [***] in respect of the Asian Plant. 

  
 - 2 -

 * Confidential treatment requested 

	 	2.1.2	Information. 

  

	 	2.1.2.1	 For the purposes of Phase 1, the following information will be supplied by BioAmber: 

 

	 	 	 [***] 

  

	 	2.1.2.2 	For the purposes of Phase 1, the following information will be supplied by PTTMCC: 

 

	 	 	 [***] 

  

	 	2.1.3	Milestones. The milestones for Phase 1 of the Work Plan are: 

  

	 	2.1.3.1	 [***] (the “Site”). 

  

	 	2.1.3.2	 [***]. 

  

	 	2.2	Phase 2. Phase 2 of the Work Plan has a target completion date of [***]. 

 

	 	2.2.1	Key Deliverables. Phase 2 of the Work Plan is comprised of the following deliverables: 

 

	 	2.2.1.1 	Finalized Site-specific engineering for the Asian Plant (adaptation of basic engineering to Site); 

 

	 	2.2.1.2 	Execution of an agreement for the lease or purchase of Site; 

  

	 	2.2.1.3 	Execution of a supply contracts for utilities, services, sugar, CO2, other raw materials; 

 

	 	2.2.1.4 	Issuance of all necessary permits for the Asia BSA JV and/or Asian Plant; 

  
 - 3 -

 * Confidential treatment requested 

	 	2.2.1.5 	Selection of the EPC firm for the Asian Plant; 

  

	 	2.2.1.6 	Secure funding for Asia BSA JV and Asian Plant. 

  

	 	2.2.2	Information. 

  

	 	2.2.2.1 	For the purposes of Phase 2, BioAmber will provide [***]; 

  

	 	2.2.3	Milestones. The milestones for Phase 2 of the Work Plan are: 

  

	 	 	[***] 

  

	 	2.3	Phase 3. Phase 3 of the Work Plan has a target completion date of [***]. 

 

	 	2.3.1	Key Deliverables. Phase 3 of the Work Plan is comprised of the following deliverables: 

 

	 	2.3.1. 1	Finalization of detailed engineering plans for the Asian Plant; 

  

	 	2.3.1.2 	Procurement of equipment for the Asian Plant; 

  

	 	2.3.1.3 	Construction of the Asian Plant; 

  

	 	2.3.1.4 	Hiring of management and staff personnel for the Asian Plant; 

  

	 	2.3.1.5 	Training of key personnel at BioAmber plant in Sarnia; 

  

	 	2.3.1.6 	Retention of an accounting firm by the Asia BSA JV to book and track costs. 

 

	 	2.3.2	Milestones. The milestones for Phase 3 of the Work Plan are: 

  

	 	 	[***] 

  

	 	2.4	Phase 4. Phase 4 of the Work Plan has a target completion date of [***]. 

 

	 	2.4.1	Key Deliverables. Phase 4 of the Work Plan is comprised of the following deliverables: 

 

	 	2.4.1.1 	Water testing at the Asian Plant; 

  

	 	2.4.1.2 	Start-up of operations at the Asian Plant. 

  
 - 4 -

 * Confidential treatment requested 

	 	2.4.2	Milestones. The milestones for Phase 4 of the Work Plan are: 

  

	 	 	[***] 

  

	3	ROLES AND RESPONSIBILITIES 

  

	 	3.1	The roles and responsibilities of each Party in connection with each Phase of the Work Plan will be agreed by the Parties prior to the commencement of such Phase.

  

	4	TRANSACTION DOCUMENTS 

  

	 	4.1	The participation of MCC and PTTMCC in the Asian BSA JV would require negotiation and execution of documents customary to such a transaction, including the following
(the “Transaction Documents”), each with customary terms, conditions, representations and warranties, including confidentiality and standstill undertakings, and, upon their execution, being binding upon the parties thereto:

  

	 	4.1.1	A joint-venture agreement between the Parties and, as the case may be, Mitsui; 

 

	 	4.1.2	An operating agreement [***]; 

  

	 	4.1.3	 A license agreement between BioAmber, as licensor, and the Asian BSA JV, as licensee, with respect to the BioAmber Technology (as defined in the
1st MOU); 

 

	 	4.1.4	An exclusive “off-take” supply agreement between the Asian BSA JV, as supplier, and PTTMCC for BSA produced by the Asian Plant. 

 

	 	4.2	The execution of the Transaction Documents by each of the Parties is subject to completion of Phase 2 of the Work Plan and the approval of the Transaction Documents by
the board of directors or the appropriate governing bodies of each of the Parties. 

  

	5	PUBLIC DISCLOSURE 

  

	 	5.1	 The Parties agree that it is their intent to publicly disclose their proposed relationship described in this Agreement, subject to the Parties agreeing
on the content of any press release and the moment of its release. The Parties agree that the initial press release attached hereto as Schedule A is approved by the Parties and is scheduled to be released on September 14th, 2011. 

  
 - 5 -

 * Confidential treatment requested 

	6	CONFIDENTIALITY 

  

	 	6.1	 This Agreement and all information exchanged by the Parties pursuant thereto (i) will remain the property of the Party providing it (ii) will
be subject to the Confidentiality Agreement dated June 21st, 2011, entered into between BioAmber S.A.S., PTTMCC and Mitsui, and (iii) will be considered confidential for a period of [***] following its disclosure. Notwithstanding the preceding, PTTMCC will
use reasonable efforts to ensure that all information disclosed by BioAmber which is submitted to the Thai government or other agencies remains confidential. 

 

	7	STANDSTILL 

  

	 	7.1	After the Parties are mutually satisfied with the feasibility study and Phase 1 of the Work Plan is completed, BioAmber will provide the basic engineering process
package. In the event that PTTMCC notifies BioAmber at the conclusion of Phase 2 of the Work Plan that it will not proceed with the Asian BSA JV or the Asian Plant, [***]. In the event that BioAmber notifies PTTMCC at the conclusion of Phase 2 of
the Work Plan that it will not proceed with the Asian BSA JV or the Asian Plant, [***]. 

  

	8	PARTICIPATION OF MITSUI 

  

	 	8.1	The parties agree that, in the event BioAmber executes definitive agreements with Mitsui concerning a Thai plant, Mitsui will automatically become a party to this
Agreement, and shall be bound by its provisions. Mitsui may participate directly in the Asia BSA JV or with BioAmber through a jointly held legal entity. 

  

	9	COSTS 

  

	 	9.1	Each Party will assume its own costs (personnel, travel, consultants, legal) in connection with this Agreement and the Work Plan. Notwithstanding the preceding, the
Parties agree to jointly pay for third party fees related to soil testing, environmental assessments, engineering and other project related costs beginning in Phase 2 of the Work Plan. 

 

	10	 ADDENDUM TO THE
2ND MOU 

  

	 	10.1	 This Agreement is an addendum to the 2nd MOU and forms an integral part thereof. Except as amended by this agreement, all provisions of the 2nd MOU remain in full force and effect between the parties.

  
 - 6 -

 * Confidential treatment requested 

 IN WITNESS WHEREOF, THE PARTIES HAVE EXECUTED THIS AGREEMENT ON THE DATE FIRST ABOVE MENTIONED.

  

			
		 	BIOAMBER INC.
		
	By:	 	/s/ Jean-François Huc
		 	Jean-François Huc
		
		 	MITSUBISHI CHEMICAL CORPORATION
		
	By:	 	/s/ [***]
		 	[***]
		
		 	PTT MCC BIOCHEM LTD.
		
	By:	 	/s/ [***]
		 	[***]

  
 - 7 -

 * Confidential treatment requested 

 SCHEDULE A 

PRESS RELEASE TO BE ISSUED ON SEPTEMBER 14th, 2011 
 BioAmber Partners with PTT MCC Biochem for PBS production in Thailand 
 Minneapolis, MN
14 September 2011 – PTT MCC Biochem (PTTMCC), a joint venture between PTT PLC and Mitsubishi Chemical, has selected BioAmber Inc. as its partner for a polybutylene succinate (PBS) plant that will begin construction in Thailand in 2012.
BioAmber will build a biobased succinic acid plant in Thailand and supply PTTMCC with biobased succinic acid on an exclusive basis. Succinic acid is the principal starting material for the production of PBS, along with 1,4-butanediol. 

PTTMCC plans to take an interest in BioAmber’s succinic acid plant and secure off-take for a portion of the plant’s capacity. The plant will be
built in proximity to PTTMCC’s PBS plant, and both plants are expected to come online in 2014. After evaluating the various biosuccinic acid technologies, PTTMCC concluded that BioAmber’s platform offered the lowest cost biosuccinic acid
with the lowest technological risk. By securing BioAmber’s cost competitive succinic acid, PTTMCC expects to drive down the manufacturing cost of biobased PBS, a renewable, biodegradable polymer that has significant growth potential and strong
patent protection thanks to a recently issued Mitsubishi Chemical patent. 
 The partners have begun a feasibility study to determine the exact
location of the succinic acid plant, which could be built next to the PBS plant at the Map Ta Phut site in Rayong. At peak capacity BioAmber expects to produce 65,000 MT of succinic acid on the site. BioAmber also plans to produce 50,000 MT of
biobased 1,4-butanediol on site, using its technology licensed exclusively from DuPont to convert biobased succinic acid directly to 1,4-butanediol in an integrated process. PTTMCC will help BioAmber secure biomass for the plant, which will
initially source sugar from cane and/or tapioca, and subsequently biomass sugars. 
 “BioAmber operates the world’s only large-scale
biobased succinic acid plant and is already Mitsubishi Chemical’s sole supplier of biobased succinic acid. BioAmber has proven the quality and cost of its biosuccinic acid and we have been working together for a number of months to further
improve the technology,’” said Shigeru Handa, General Manager of Mitsubishi Chemical’s Sustainable Resources Business Development Department and a member of the PTTMCC board of directors. “Partnering with BioAmber will allow
PTTMCC to have competitive biosuccinic acid from a local source by 2014” he added. 
 “Securing the lowest cost succinic acid was a
priority for PTTMCC” said Worawat Pitayasiri, Managing Director of PTTMCC. “BioAmber’s commitment to building a large scale plant in Thailand will benefit our company and represents a major investment in Thailand by a leading US-based
renewable chemicals company,” he added. 
 “This partnership is a testament to our market leadership in succinic acid. We are proud
that PTTMCC Biochem chose BioAmber as the succinic acid supplier for its PBS venture,” added Jean-Francois Huc, the CEO of BioAmber. “With its strong patent portfolio, PTTMCC Biochem is poised to be the dominant player in biobased PBS and
this partnership gives BioAmber a strong position in a fast growing segment of the biosuccinic acid market,” he added. 

  
 - 8 -

 * Confidential treatment requested 

 About BioAmber Inc. 
 BioAmber, a renewable chemistry company, is the market leader in the development and commercialization of biobased succinic acid and derivatives including modified PBS, a biodegradable plastic offering
better heat resistance and processability than other biopolymers. BioAmber operates the world’s only large-scale biobased succinic acid plant and has partnerships with market leaders including Cargill, DuPont Applied Biosciences,
Mitsui & Co., Mitsubishi Chemical and PTTMCC Biochem. BioAmber is also leveraging its succinic acid experience and know-how to develop a biobased adipic acid platform. The company has offices and research labs in Minneapolis, MN, an office
in Montreal, a sales office in Shanghai, China and a production plant in Pomacle, France. For more information, see www.bio-amber.com. 

About PTT MCC Biochem Company Limited 

PTT MCC Biochem was established to develop and produce Polybutylene Succinate or PBS, a biodegradable plastic that is derived from sugar with a lower
carbon footprint than conventional plastics. The company is a joint venture between PTT Public Company Limited (PTT) of Thailand and Mitsubishi Chemical Corporation (MCC) of Japan with the shareholding proportion of 50% each. The company has the
head office in Bangkok, and the plant site is expected to be in Map Ta Phut, Rayong, Thailand. 
 BioAmber Media Contact

 Kathryn Sheridan 

Sustainability Consult 

ks@sustainabilityconsult.com 
 Phone: 202 470
3239 (US) / +32 496 116198 (Europe) 
 BioAmber Investor Relations 
 Mike Hartmann 
 Executive Vice President 
 mike.hartmann@bio-amber.com 
 Phone: 514 844 8000 extension 120 

PTT MCC Biochem Contact 

Rathakorn Kampanathsanyakorn 
 Manager, Business
Development & Planning Department 
 PTTMCC Biochem Company Limited 
 rathakorn.k@pttplc.com 
 Tel: +66 2 537 3637 

  
 - 9 -

 * Confidential treatment requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]